---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017593"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:42:49.590441+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xilio reports XTX202 Phase 1/2 data: 50% disease control at ≥2.8 mg/kg, no vascular leak syndrome

## Summary
- 62 patients dosed; 42 evaluable for activity: 31% disease control rate (13 SD ≥9 wks) across all doses, 50% at ≥2.8 mg/kg (3/6).
- No signs/symptoms of vascular leak syndrome; TRAEs primarily Grade 1-2; no discontinuations due to TRAE.
- Two patients on treatment >1 year (MSS CRC and RCC); dose-dependent PK with ~15% activated drug in tumor vs <1% in plasma.
- Plan to evaluate XTX202 at 4.0 mg/kg in Phase 2 for melanoma and RCC; initial data expected Q2 2024.
- Milestones subject to additional capital: XTX101 combo Phase 2 start Q3 2024, XTX301 data H2 2024.

## SEC filing metadata
- accession: 0001558370-23-017593
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023017593/0001558370-23-017593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023017593/xlo-20231103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017593
- JSON: https://secwatch.observer/filing/0001558370-23-017593.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017593.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.